These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
102 related articles for article (PubMed ID: 3219056)
1. [The antineoplastic action of o-substituted [1,2-bis(4-hydroxyphenyl)-ethylenediamine]dichloroplatinum (II) complexes and their methylethers]. Karl J; Schönenberger H Arch Pharm (Weinheim); 1988 Jul; 321(7):405-10. PubMed ID: 3219056 [No Abstract] [Full Text] [Related]
2. Tumor-inhibiting [1,2-bis(fluorophenyl)ethylenediamine]platinum(II) complexes. V. Synthesis and evaluation of enantiomeric [1,2-bis-(4-fluorophenyl)ethylenediamine]dichloroplatinum(II) complexes. vom Orde HD; Reile H; Müller R; Gust R; Bernhardt G; Spruss T; Schönenberger H; Burgemeister T; Mannschreck A J Cancer Res Clin Oncol; 1990; 116(5):434-8. PubMed ID: 2229132 [TBL] [Abstract][Full Text] [Related]
3. Tumor inhibiting properties of stereoisomeric [1,2-bis(3-hydroxyphenyl)ethylenediamine]dichloroplatinum(II)-compl exe s, Part I: Synthesis. Jennerwein M; Gust R; Müller R; Schönenberger H; Engel J; Berger MR; Schmähl D; Seeber S; Osieka R; Atassi G Arch Pharm (Weinheim); 1989 Jan; 322(1):25-9. PubMed ID: 2730286 [TBL] [Abstract][Full Text] [Related]
4. Tumor inhibiting properties of stereoisomeric [1,2-bis(3-hydroxyphenyl) ethylenediamine]dichloroplatinum(II)-complexes, Part II: Biological properties. Jennerwein M; Gust R; Müller R; Schönenberger H; Engel J; Berger MR; Schmähl D; Seeber S; Osieka R; Atassi G Arch Pharm (Weinheim); 1989 Feb; 322(2):67-73. PubMed ID: 2730292 [TBL] [Abstract][Full Text] [Related]
5. Mammary tumor inhibiting properties of the (S,S)-configurated [1,2-bis(4-hydroxyphenyl)ethylenediamine]dichloroplatinum(II) complex. Spruss T; Gust R; Müller R; Engel J; Schönenberger H Arch Pharm (Weinheim); 1990 Feb; 323(2):99-102. PubMed ID: 2334275 [TBL] [Abstract][Full Text] [Related]
6. Platinum and palladium complexes containing ethylenediamine derivatives as carrier ligands and their antitumor activity. Lee K; Tashiro T; Noji M Chem Pharm Bull (Tokyo); 1994 Mar; 42(3):702-3. PubMed ID: 8004720 [TBL] [Abstract][Full Text] [Related]
7. Tumor inhibiting [1,2-bis(difluorophenyl)ethylenediamine]dichloroplatinum (II) complexes, I: Synthesis. Müller R; Schickaneder E; Jennerwein M; Reile H; Spruss T; Engel J; Schönenberger H Arch Pharm (Weinheim); 1991 Feb; 324(2):115-20. PubMed ID: 1854235 [TBL] [Abstract][Full Text] [Related]
8. [Antitumor platinum(II) complexes with substituted 2-aminomethylpyridine ligands]. Brunner H; Nerl G; von Angerer E; Knebel N Arch Pharm (Weinheim); 1991 Oct; 324(10):779-84. PubMed ID: 1805710 [TBL] [Abstract][Full Text] [Related]
9. Different response of murine and human mammary tumour models to a series of diastereoisomeric [1,2-bis(difluorophenyl) ethylenediamine]dichloroplatinum(II) complexes. Spruss T; Bernhardt G; Schickaneder E; Schönenberger H J Cancer Res Clin Oncol; 1991; 117(5):435-43. PubMed ID: 1890139 [TBL] [Abstract][Full Text] [Related]
10. [1,2-Bis(2-hydroxyphenyl)ethylenediamine]dichloroplatinum(II), a new compound for the therapy of ovarian cancer. II. Synthesis and preliminary testing of the enantiomeric complexes. Bernhardt G; Gust R; Reile H; vom Orde HD; Müller R; Keller C; Spruss T; Schönenberger H; Burgemeister T; Mannschreck A J Cancer Res Clin Oncol; 1992; 118(3):201-8. PubMed ID: 1548285 [TBL] [Abstract][Full Text] [Related]
11. Aqua[1,1-bis(4-hydroxyphenyl)-1,2-diamino-2-phenylethane]- sulfatoplatinum(II), a new compound for the treatment of the mammary carcinoma. Gust R Arch Pharm (Weinheim); 1994 Jan; 327(1):49-54. PubMed ID: 8117188 [TBL] [Abstract][Full Text] [Related]
12. Stereoisomeric [1,2-bis(3-hydroxyphenyl)ethylenediamine]platinum(II) complexes, Part III: Evaluation of the mammary tumor inhibiting properties. Schertl S; Gust R; Müller R; Spruss T; Schönenberger H Arch Pharm (Weinheim); 1992 Feb; 325(2):113-8. PubMed ID: 1605715 [TBL] [Abstract][Full Text] [Related]
13. Reduction of the estrogenic side effects of the mammary tumor-inhibiting drug [1,2-bis(2,6-dichloro-4-hydroxyphenyl)- ethylenediamine]dichloroplatinum(II) by variation of ring substituents. Gust R; Karl J; Faderl M; Schönenberger H Arch Pharm (Weinheim); 1995 May; 328(5):457-63. PubMed ID: 7611841 [TBL] [Abstract][Full Text] [Related]
14. Does [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]- dichloroplatinum(II) act on the hormone-sensitive, murine breast cancer as a biological response modifier? Part II. Studies on the influence of [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine] dichloroplatinum(II) on the specific immune defense in MXT-M-3,2 breast cancer bearing mice. Schlemmer R; Spruss T; Bernhardt G; Schönenberger H Arch Pharm (Weinheim); 2000 Dec; 333(12):397-403. PubMed ID: 11199469 [TBL] [Abstract][Full Text] [Related]
15. Synthesis, mutagenicity, binding to pBR 322 DNA and antitumour activity of platinum(II) complexes with ethambutol. Coluccia M; Fanizzi FP; Giannini G; Giordano D; Intini FP; Lacidogna G; Loseto F; Mariggio MA; Nassi A; Natile G Anticancer Res; 1991; 11(1):281-7. PubMed ID: 2018362 [TBL] [Abstract][Full Text] [Related]
16. Aqua[1-(2,6-dichloro-4-hydroxyphenyl)-2- phenylethylenediamine](sulfato)platinum-(II) complexes with variable substituents in the 2-phenyl ring. 1. Synthesis and antitumor and estrogenic properties. Gust R; Burgemeister T; Mannschreck A; Schönenberger H J Med Chem; 1990 Sep; 33(9):2535-44. PubMed ID: 2391694 [TBL] [Abstract][Full Text] [Related]
17. A water-soluble 1,2-diaminocyclohexaneplatinum(II) complex containing procaine hydrochloride: synthesis and antiproliferative activity in vitro. Cafaggi S; Esposito M; Parodi B; Viale M Pharmazie; 1994 Aug; 49(8):617-8. PubMed ID: 7938154 [No Abstract] [Full Text] [Related]
18. Comparison of the effectivity of two diaminocyclohexane Pt-complexes. Balázová E; Hrubisko M; Ujházy V Neoplasma; 1985; 32(5):537-42. PubMed ID: 4069288 [TBL] [Abstract][Full Text] [Related]
19. New platinum (II) and platinum (IV) complexes with 1,2-diaminocyclohexane. Synthesis and in vitro and in vivo antitumour evaluation. Craciunescu DG; Furlani Candiani A; Scarcia V; Doadrio A; Ghirvu C J Pharm Belg; 1985; 40(2):79-84. PubMed ID: 4009393 [No Abstract] [Full Text] [Related]
20. Tumor inhibiting [1,2-bis(fluorophenyl)ethylenediamine]platinum(II) complexes. Part IV: Biological evaluation--in vivo studies on the P 388 leukemia. Reile H; Spruss T; Bernhardt G; Müller R; Gust R; Schönenberger H Arch Pharm (Weinheim); 1991 Jul; 324(7):405-9. PubMed ID: 1763951 [No Abstract] [Full Text] [Related] [Next] [New Search]